Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVO NASDAQ:CORV NASDAQ:OHRP NASDAQ:PRPH NASDAQ:VVUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$3.00-0.3%$4.86$2.81▼$485.37$2.28M5.58611,342 shs128,320 shsCORVCorrevio Pharma$0.42$0.41$0.21▼$2.79$27.80M0.085.35 million shsN/AOHRPOHR Pharmaceutical$7.37$1.60▼$6.28$1.08M0.84180,228 shsN/APRPHProPhase Labs$0.42-1.5%$0.36$0.22▼$3.55$17.85M-0.413.15 million shs354,394 shsVVUSVIVUS$0.37$0.44▼$4.75$7.33M-0.841.44 million shs2.03 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics-0.99%-0.33%-35.55%-85.10%-99.96%CORVCorrevio Pharma0.00%0.00%0.00%0.00%0.00%OHRPOHR Pharmaceutical0.00%0.00%0.00%0.00%0.00%PRPHProPhase Labs+1.34%+5.86%+22.84%+39.32%-87.61%VVUSVIVUS0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPVOAptevo Therapeutics2.1832 of 5 stars3.53.00.00.00.60.01.3CORVCorrevio PharmaN/AN/AN/AN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/APRPHProPhase Labs0.4938 of 5 stars0.05.00.00.00.00.00.6VVUSVIVUSN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 3.00Buy$219,040.007,301,233.33% UpsideCORVCorrevio Pharma 0.00N/AN/AN/AOHRPOHR Pharmaceutical 0.00N/AN/AN/APRPHProPhase Labs 0.00N/AN/AN/AVVUSVIVUS 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo Therapeutics$3.11M0.73N/AN/A$65.21 per share0.05CORVCorrevio Pharma$32.63M0.85N/AN/A($0.02) per share-21.00OHRPOHR PharmaceuticalN/AN/AN/AN/A$3.86 per shareN/APRPHProPhase Labs$6.77M2.60N/AN/A$0.25 per share1.69VVUSVIVUS$69.76M0.00N/AN/A($6.50) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-779.42%-175.59%8/6/2025 (Estimated)CORVCorrevio Pharma-$35.18M-$0.79N/A∞N/A-107.81%-2,128.82%-58.56%N/AOHRPOHR Pharmaceutical-$13.23MN/A0.00N/AN/AN/A-75.46%-71.18%N/APRPHProPhase Labs-$53.36M-$1.26N/AN/AN/AN/A-184.38%-64.59%8/13/2025 (Estimated)VVUSVIVUS-$31.50M-$2.96N/AN/AN/A-39.28%N/A-12.18%N/ALatest APVO, PRPH, CORV, VVUS, and OHRP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025PRPHProPhase Labs-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million5/15/2025Q1 2025APVOAptevo Therapeutics-$84.20-$87.80-$3.60-$4.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ACORVCorrevio PharmaN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/AVVUSVIVUSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A0.670.67CORVCorrevio Pharma22.541.070.95OHRPOHR PharmaceuticalN/A3.733.73PRPHProPhase Labs0.301.030.98VVUSVIVUSN/A0.430.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%CORVCorrevio Pharma7.30%OHRPOHR Pharmaceutical10.70%PRPHProPhase Labs9.45%VVUSVIVUS7.32%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.01%CORVCorrevio PharmaN/AOHRPOHR Pharmaceutical12.50%PRPHProPhase Labs9.60%VVUSVIVUS12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics50760,000756,000Not OptionableCORVCorrevio Pharma13366.19 millionN/AOptionableOHRPOHR Pharmaceutical32.83 millionN/ANot OptionablePRPHProPhase Labs13041.54 million37.55 millionOptionableVVUSVIVUS5717.87 millionN/AOptionableAPVO, PRPH, CORV, VVUS, and OHRP HeadlinesRecent News About These CompaniesVIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin LymphomaApril 14, 2025 | globenewswire.comVIVUS' QSYMIA® to be Featured on Health Uncensored with Dr. DrewMarch 19, 2025 | globenewswire.comVIVUS Launches QSYMIA® in the United Arab EmiratesMarch 10, 2025 | globenewswire.comVIVUS Unveils Global Initiative to Advance Healthy and Sustainable Weight ManagementMarch 4, 2025 | globenewswire.comVIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025January 13, 2025 | globenewswire.comVIVUS Shares Significant Regulatory Update on QSYMIA®October 28, 2024 | globenewswire.comVIVUS Announces Label Update for QSYMIA®October 23, 2024 | tmcnet.comGeorgia rapper pleads guilty to federal gang, drug charges; asked for gun at movie theaterAugust 16, 2024 | wsbtv.comWVIVUS Provides Update on Pipeline and Program MilestonesJanuary 8, 2024 | markets.businessinsider.comShark research group to build new global headquarters in Jacksonville with help from state fundingJune 26, 2023 | actionnewsjax.comAMetaview announces Answers, the world's first conversational AI for the interview processMay 25, 2023 | it.tmcnet.comPancrelipase (CAS 53608-75-6) Market 2023 | Industry Growth ... - StreetBuzzMay 12, 2023 | news.google.comNExploring Huge Demand of Peripherally Acting Anti-Obesity Drug ... - Digital JournalMay 12, 2023 | news.google.comNExtensive Growth Opportunities to be Witnessed by Prescription Weight-Loss Pills Market 2023 Analysis of Risin - openPRMay 11, 2023 | news.google.comNErectile Dysfunction Drugs Market to Register High Demand Rate by ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comNMilestone Pharmaceuticals Reports First Quarter 2023 Financial ... - PR NewswireMay 11, 2023 | news.google.comNAnti-obesity Therapeutics Market to Witness the Highest Growth ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comNAnti Obesity Drugs Market Future Industry Scope for New ... - Digital JournalMay 11, 2023 | news.google.comNThis Crazy Six-Wheel Hatchback by Briggs & Stratton Was One of ... - autoevolutionMay 10, 2023 | news.google.comNProstatic Artery Embolization Market Current and Upcoming Projects ... - Digital JournalMay 9, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPVO, PRPH, CORV, VVUS, and OHRP Company DescriptionsAptevo Therapeutics NASDAQ:APVO$3.00 -0.01 (-0.33%) Closing price 04:00 PM EasternExtended Trading$2.98 -0.02 (-0.67%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Correvio Pharma NASDAQ:CORVCorrevio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.OHR Pharmaceutical NASDAQ:OHRPOHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.ProPhase Labs NASDAQ:PRPH$0.42 -0.01 (-1.47%) Closing price 03:59 PM EasternExtended Trading$0.42 -0.01 (-1.77%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.VIVUS NASDAQ:VVUSVIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
